IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Their pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. 

Biotechnology

IO Biotech

Mai-Britt Zocca

Misbah Sherwani

Qasim Ahmad

Devin Smith

Eric Faulkner

Amy Sullivan

Brian Burkavage

Ayako Wakatsuki Pedersen

Margaret Siemon-Hryczyk

Dan Mannix

Diane Mcdowell

Muhammad Al-Hajj

The Research and Development team at IO Biotech is responsible for advancing the company's innovative immune therapies for cancer treatment. This team conducts cutting-edge research to develop and optimize their unique platform technology, which activates T cells specific to immune inhibitory molecules, ultimately aiming to bring first-in-class immune modulating therapies from the lab to clinical trials.

Research and Development

Regulatory and Clinical Operations

Clinical Operations Team

Research and Development

About

Team members

Other teams at IO Biotech

Regulatory and Clinical Operations

Clinical Operations Team